Thalidomide and lenalidomide in primary myelofibrosis

Netherlands Journal of Medicine

Volumn 68, Issue 7-8, 2010, Pages 293-298

  Holle, N ^a   de Witte, T ^a   Mandigers, C ^b   Schaap, N ^a   Raymakers, R ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Lenalidomide; Myelofibrosis; Myeloproliferative neoplasm; Thalidomide

Indexed keywords

JANUS KINASE 2; LENALIDOMIDE; THALIDOMIDE;

CYTOKINE PRODUCTION; CYTOPENIA; ERYTHROCYTE TRANSFUSION; GENE MUTATION; HUMAN; MYELOFIBROSIS; NEUROPATHY; PANCYTOPENIA; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; HEMATOPOIESIS; HUMANS; JANUS KINASE 2; PREDNISONE; PRIMARY MYELOFIBROSIS; THALIDOMIDE;

EID: 77957735518     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Tefferi A. Myelofibrosis with myeloid Metaplasia. N Engl J Med. 2000; 342:1255-65.
2. Cervantes F. Myelofibrosis: biology and treatment options. Eur J Haematol Suppl. 2007;(68):13-7. Review.
3. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-90.
4. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-70.
5. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901.
6. Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, Isidori A, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002;16(9):1609-14.
7. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158-64.
8. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101(7):2534-41.
9. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114(1):78-83.
10. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79(7):883-9.
11. Benetatos L, Chaidos A, Alymara V, Vassou A, Bourantas KL. Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. Eur J Haematol. 2005;74(3):273-4.
12. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006;106(9):1974-84.
13. Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, et al for Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS). Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica. 2006;91(8):1027-32.
14. Berrebi A, Feldberg E, Spivak I, Shvidel L. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. Haematologica. 2007;92(2):e15-6.
15. Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN. Low-dose thalidomide in myelofibrosis. Haematologica. 2008;93(7):1100-1.
16. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100(9):3063-7.
17. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22(3):424-31.
18. Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;117(2):288-96.
19. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299-307.
20. Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, et al. Lenalidomide plus prednisone results in durable clinica;, histopahtologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009; 27(28):4760-6.
21. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009; 27(27):4563-9.